Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel Sells 6,667 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) COO Anish Patel sold 6,667 shares of the company's stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $20.34, for a total value of $135,606.78. Following the sale, the chief operating officer now owns 303,309 shares in the company, valued at approximately $6,169,305.06. This trade represents a 2.15% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Anish Patel also recently made the following trade(s):

• On Wednesday, May 7th, Anish Patel sold 6,667 shares of Enliven Therapeutics stock. The stock was sold at an average price of $18.39, for a total value of $122,606.13.
• On Monday, April 7th, Anish Patel sold 6,667 shares of Enliven Therapeutics stock. The stock was sold at an average price of $18.04, for a total value of $120,272.68.

Enliven Therapeutics Stock Up 11.4%

NASDAQ:ELVN traded up $2.25 during mid-day trading on Friday, reaching $21.91. 3,224,928 shares of the stock were exchanged, compared to its average volume of 285,750. The company has a 50 day simple moving average of $18.30 and a 200-day simple moving average of $20.67. The stock has a market capitalization of $1.08 billion, a P/E ratio of -11.53 and a beta of 0.79. Enliven Therapeutics, Inc. has a 1 year low of $13.30 and a 1 year high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.06). As a group, research analysts predict that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC grew its stake in Enliven Therapeutics by 230.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company's stock worth $36,000 after buying an additional 1,114 shares during the last quarter. GAMMA Investing LLC lifted its position in Enliven Therapeutics by 3,058.1% during the 1st quarter. GAMMA Investing LLC now owns 2,716 shares of the company's stock worth $53,000 after acquiring an additional 2,630 shares during the period. Quantbot Technologies LP acquired a new stake in Enliven Therapeutics during the 1st quarter worth approximately $60,000. KLP Kapitalforvaltning AS acquired a new stake in Enliven Therapeutics during the 4th quarter worth approximately $97,000. Finally, BNP Paribas Financial Markets acquired a new stake in Enliven Therapeutics during the 4th quarter worth approximately $112,000. Hedge funds and other institutional investors own 95.08% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. HC Wainwright increased their price objective on Enliven Therapeutics from $39.00 to $40.00 and gave the company a "buy" rating in a report on Thursday, May 15th. Jones Trading dropped their price objective on Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating on the stock in a report on Friday, May 16th.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.